You are here

Article info

Article menu

Download PDFPDF

Electronic pages
Correspondence
Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials
Free

Authors

  • Josefina Durán Department of Rheumatology, Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile PubMed articlesGoogle scholar articles
  • David T Felson Clinical Epidemiology Unit, School of Medicine, Boston University, Boston, Massachusetts, USA Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester, Manchester, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Josefina Durán, Department of Rheumatology, Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile; jgduran{at}uc.cl
View Full Text

Citation

Durán J, Felson DT
Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials
Annals of the Rheumatic Diseases 2016;75:e53.

Publication history

  • Received April 26, 2016
  • Accepted April 29, 2016
  • First published May 24, 2016.
Online issue publication 
October 31, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/